ArticleMolecular biology reports2026
Molecular analysis of FSHR rs6166 polymorphism and oxidative stress parameters in women with polycystic ovary syndrome.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder associated with hormonal dysregulation, oxidative stress, and genetic susceptibility. The follicle-stimulating hormone receptor (FSHR) rs6166 polymorphism has been investigated for its potential association with ovarian function and PCOS. In addition, regarding FSHR rs6166 polymorphism in PCOS, limited data are available from Kurdistan Region-Iraqi women. PURPOSE: Molecular analysis of FSHR rs6166 polymorphism, oxidative stress markers and hormonal profile in women with PCOS. Gene interaction networks, anthropometric and reproductive characteristics of PCOS were another main aim of current study. METHODOLOGY: Blood samples from PCOS patients and healthy controls were collected for molecular, hormonal and oxidative stress assessments. FSHR rs6166 polymorphism was analyzed by polymerase chain reaction (PCR) and Sanger sequencing. In silico analyses were performed using Genome Aggregation Database (gnomAD) and GeneMANIA databases.
resultsThe rs6166 variant was highly prevalent in both PCOS patients (84.21%) and controls (80.00%), predominantly in heterozygous form. Women with PCOS demonstrated significantly reduced follicle-stimulating hormone (FSH), progesterone (PROG), and superoxide dismutase (SOD) levels, alongside elevated estradiol concentrations (p < 0.05). Variant carriers showed lower antioxidant marker levels, particularly SOD and total antioxidant capacity (T-AOC). In silico analysis identified rs6166 as a missense coding variant within the FSHR gene. GeneMANIA predicted interactions between FSHR and multiple genes associated with reproductive function, providing supportive bioinformatic context for the observed associations.
conclusionFSHR rs6166 polymorphism may associate with PCOS susceptibility through its interaction with reproductive regulatory pathways and oxidative stress imbalance. Gene interaction analysis further supports the potential biological relevance of FSHR in pathways associated with PCOS.
Indexed as
Identifiers
42377768What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.